1-(5-(4-fluorophenyl)thiazol-2-yl)propan-1-ol | 1429330-50-6

• 分子结构分类: 有机化合物
• 英文名称: 1-(5-(4-fluorophenyl)thiazol-2-yl)propan-1-ol
• 英文别名: 1-[5-(4-fluorophenyl)-1,3-thiazol-2-yl]propan-1-ol
• CAS: 1429330-50-6
• 化学式: C₁₂H₁₂FNOS
• 分子量: 237.298
• InChiKey: ZCSPVDZRCJECCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-(4-Fluorophenyl)thiazole-2-carbaldehyde 、 乙基溴化镁 在 crude compound 、 silica gel 、 乙酸乙酯 、 正己烷 作用下， 以to give 1-(5-(4-fluorophenyl)thiazol-2-yl)propan-1-ol as pale yellow liquid (0.1 g, 73% yield)的产率得到1-(5-(4-fluorophenyl)thiazol-2-yl)propan-1-ol
  参考文献：
  名称：

  Pyridine derivatives

  摘要：

  本申请提供了新型吡啶化合物及其药学上可接受的盐或前药。同时还提供了制备这些化合物的方法。通过向患者投予一种或多种化合物的治疗有效剂量，这些化合物对于抑制CYP17活性是有用的。通过这样做，这些化合物对于治疗与CYP17活性相关的疾病是有效的。这些化合物可以治疗多种疾病，包括由异常细胞增殖所特征的疾病。在一种实施方式中，该疾病是癌症，如前列腺癌。

  公开号：

  US09266873B2

文献信息

• [EN] PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS PYRIDINES
  申请人：ENDO PHARMACEUTICALS INC

  公开号：WO2013049559A1

  公开（公告）日：2013-04-04

  The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP 17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CPY17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.

  本申请提供了新型的吡啶化合物及其药用可接受的盐或前药。同时，还提供了制备这些化合物的方法。这些化合物通过向患者施用一种或多种化合物的治疗有效量，用于抑制CYP 17活性。通过这样做，这些化合物有效地治疗与CPY17活性相关的病症。可以使用这些化合物治疗多种病症，包括以异常细胞增殖为特征的疾病。在一个实施例中，所述疾病为癌症，如前列腺癌。
• PYRIDINE DERIVATIVES
  申请人：Asana BioSciences, LLC

  公开号：US20170073339A1

  公开（公告）日：2017-03-16

  The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.

  本申请提供了新型吡啶化合物及其药学上可接受的盐或前药。还提供了制备这些化合物的方法。通过向患者投入一种或多种化合物的治疗有效剂量，这些化合物可用于抑制CYP17活性。通过这样做，这些化合物可有效治疗与CYP17活性有关的疾病。这些化合物可用于治疗多种疾病，包括以异常细胞增殖为特征的疾病。在一种实施方式中，该疾病是癌症，如前列腺癌。
• Pyridine Derivatives
  申请人：Endo Pharmaceuticals Inc.

  公开号：US20130085148A1

  公开（公告）日：2013-04-04

  The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CPY17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.

  本申请提供了新型吡啶化合物及其药学上可接受的盐或前药。同时还提供了制备这些化合物的方法。这些化合物可以通过向患者投予治疗有效量的一个或多个化合物来抑制CYP17活性。通过这样做，这些化合物对于治疗与CPY17活性相关的疾病是有效的。这些化合物可以用于治疗各种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症，如前列腺癌。
• US8809372B2
  申请人：——

  公开号：US8809372B2

  公开（公告）日：2014-08-19
• US9266873B2
  申请人：——

  公开号：US9266873B2

  公开（公告）日：2016-02-23